Thrombotic microangiopathy associated with hematopoietic stem cell transplantation: general characteristics and an example from clinical practice

Associated hematopoietic stem cell transplantation (HSCT) or transplant-associated thrombotic microangiopathy (TA-TMA) is currently a generally recognized and severe complication of HSCT with a high risk of mortality. TMA is characterized by microangiopathic hemolytic anemia and thrombocytopenia, resulting in the accumulation of platelets in the microvasculature, which leads to dysfunction of the ischemic organ. The pathogenesis of TА-TMA is based on endothelial damage by various trigger factors (in particular, chemotherapeutic agents in the conditioning regimen, the use of calcineurin inhibitors, alloreactivity, infectious agents). The article presents the peculiarities of terminology, pathogenesis and clinical manifestations of TA-TMA, methods of therapy for this pathology. Examples of management of patients with TA-TMA are demonstrated using a clinical example.

1. Jodele S., Laskin B.L., Dandoy C.E., Myers K.C., El-Bietar J., Davies S.M., Goebel J., Dixon B.P. A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 2015;29(3):191‒204. doi:10.1016/j.blre.2014.11.001.

2. Carreras E., Dufour C., Mohty M., Kröger N. (eds.). The EBMT Handbook. Hematopoietic Stem Cell Transplantation and Cellular Therapies. This Springer, 2019. 688 р.

3. Scully M., Cataland S., Coppo P., de la Rubia J., Friedman K.D., Hovinga J.K., Lämmle B., Matsumoto M., Pavenski K., Sadler Е., Sarode R., Wu H.; International Working Group for Thrombotic Thrombocytopenic Purpura. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 2017;15:312–22. doi: 10.1111/jth.13571.

4. Jodele S., Zhang K., Zou F., Laskin B., Dandoy C.E., Myers K.C., Lane А., Meller J., Medvedovic M., Chen J., Davies S.M. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood 2016;127:989–96. doi: 10.1182/blood-2015-08-663435.

5. Khosla J., Yeh A.C., Spitzer T.R., Dey B.R. Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies. Bone Marrow Transplant 2018;53:129–37. doi: 10.1038/bmt.2017.207.

6. Jodele S., Davies S.M., Lane A., Khoury J., Dandoy C., Goebel J., Myers K., Grimley M., Bleesing J., El-Bietar J., Wallace G., Chima R.S., Paff Z., Laskin B.L. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 2014;124:645–53. doi: 10.1182/blood-2014-03-564997.

7. Ho V.T., Cutler C., Carter S., Martin P., Adams R., Horowitz M., Ferrara J., Soiffer R., Giralt S. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005;11:571–5. doi: 10.1016/j.bbmt.2005.06.001.

8. Ruutu T., Barosi G., Benjamin R.J., Clark R.E., George J.N., Gratwohl A., Holler E., Iacobelli M., Kentouche K., Lämmle B., Moake J.L., Richardson P., Socié G., Zeigler Z., Niederwieser D., Barbui T.; European Group for Blood and Marrow Transplantation; European LeukemiaNet. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007;92:95–100. doi: 10.3324/haematol.10699.

9. Cho B.S., Yahng S.A., Lee S.E., Eom K.S., Kim Y.J., Kim H.J., Lee S., Min C.K., Cho G.S., Kim D.W., Lee J.W., Min W.S., Park C.W. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation 2010;90:918–26. doi: 10.1097/tp.0b013e3181f24e8d.

10. Ruutu T., Hermans J., Niederwieser D., Gratwohl A., Kiehl M., Volin L., Bertz H., Ljungman P., Spence D., Verdonck L.F., Prentice H.G., Bosi A., du Toit C.E., Brinch L., Apperley J.F.; EBMT Chronic Leukaemia Working Party. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002;118:1112–9. doi: 10.1046/j.1365-2141.2002.03721.x.

11. George J.N., Selby G.B. Thrombotic microangiopathy after allogeneic bone marrow transplantation: a pathologic abnormality associated with diverse clinical syndromes. Bone Marrow Transplant 2004;33:1073–4. doi: 10.1038/sj.bmt.1704513.

12. Uderzo C.C., Jodele S., Missiry M.E., Ciceri F., Busca A., Bacigalupo A., Corbacioglu S. Transplant-associated thrombotic microangiopathy (TA-TMA) and consensus based diagnostic and therapeutic recommendations: which TA-TMA patients to treat and when? J Bone Marrow Res 2014;2:152–9. doi: 10.4172/2329-8820.1000152.

13. Yeates L., Slatter M.A., Bonanomi S., Lim F.L.W.I., Ong S.Y., Dalissier A., Barberi W., Shulz A., Duval M., Heilmann C., Willekens A., Hwang W.H.Y., Uderzo C., Bader P., Gennery A.R. Use of defibrotide to treat transplant-associated thrombotic microangiopathy: a retrospective study of the paediatric diseases and inborn errors working parties of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplant 2017;52:762–4. doi:10.1038/bmt.2016.351.

14. Jodele S., Fukuda T., Mizuno K., Vinks A.A., Laskin B.L., Goebel J., Dixon B.P., Chima R.S., Hirsch R, Teusink A., Lazear D., Lane A., Myers K.C., Dandoy C.E., Davies S.M. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2016;22(2):307‒15. doi: 10.1016/j.bbmt.2015.10.002.

15. Uderzo C., Bonanomi S., Busca A., Renoldi M., Ferrari P., Iacobelli M., Morreale G., Lanino E., Annaloro C., Della Volpe A., Alessandrino P., Longoni D., Locatelli F., Sangalli H., Rovelli A. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 2006;82:638‒44. doi: 10.1097/01.tp.0000230373.82376.46.

16. Narimatsu H., Kami M., Hara S., Matsumura T., Miyakoshi S., Kusumi E., Kakugawa Y., Kishi Y., Murashige N., Yuji K., Masuoka K., Yoneyama A., Wake A., Morinaga S., Kanda Y. Intestinal thrombotic microangiopathy following reduced-intensity umbilical cord blood transplantation. Bone Marrow Transplant 2005;36:517‒23. doi: 10.1038/sj.bmt.1705099.

17. Corti P., Uderzo C., Tagliabue A., Della Volpe A., Annaloro C., Tagliaferri E., Balduzzi A. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant 2002;29:542‒3. doi: 10.1038/sj.bmt.1703414.

18. Davì G., Catalano I., Belvedere M., Amato S., Mogavero A., Giammarresi C., Alaimo P., Notarbartolo A. Effects of defibrotide on fibrinolytic activity in diabetic patients with stable angina pectoris. Thromb Res 1992;65:211‒20. doi: 10.1016/0049-3848(92)90241-2.

19. Cella G., Sbarai A., Mazzaro G., Motta G., Carraro P., Andreozzi G.M., Hoppensteadt D.A., Fareed J. Tissue factor pathway inhibitor release induced by defibrotide and heparins. Clin Appl Thromb Hemost 2001;7:225‒8. doi: 10.1177/107602960100700308.

20. Falanga A., Vignoli A., Marchetti M., Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003;17:1636‒42. doi: 10.1038/sj.leu.2403004.

21. Palmer K.J., Goa K.L. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 1993;45:259‒94. doi: 10.2165/00003495-199345020-00007.

22. Laskin B.L., Goebel J., Davies S.M., Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation associated thrombotic microangiopathy. Blood 2011;118:1452‒62. doi: 10.1182/blood-2011-02-321315.

23. Richardson P.G., Corbacioglu S., Ho V.T., Kernan N.A., Lehmann L., Maguire C., Maglio M., Hoyle M., Sardella M., Sergio G., Holler E., Carreras E., Niederwieser D., Soiffer R. Drug safety evaluation of defibrotide. Expert Opin Drug Saf 2013;12:123‒36. doi: 10.1517/14740338.2012.749855.

24. Marr H., McDonald E.J., Merriman E., Smith M., Mangos H., Stoddart C., Ganly P. Successful treatment of transplant-associated microangiopathy with rituximab. N Z Med J 2009;122:72‒4. doi: 10.1182/blood.V112.11.4337.4337.

25. Carella A.M., DʼArena G., Greco M.M., Nobile M., Cascavilla N. Rituximab for allo-SCT-associated thrombotic thrombocytopenic purpura. Bone Marrow Transplant 2008;41:1063‒5. doi: 10.1038/bmt.2008.25.

26. Au W.Y., Ma E.S., Lee T.L., Ha S.Y., Fung A.T., Lie A.K.W., Kwong Y.L. Successful treatment of thrombotic microangiopathy after hematopoietic stem cell transplantation with rituximab. Br J Haematol 2007;137:475‒8. doi: 10.1111/j.1365-2141.2007.06588.x.

27. Emirova Kh.M., Orlova O.M., Muzurov A.L., Generalova G.A., Pankratenko T.E., Abaseeva T.Yu., Shatalov P.A., Kozina A.A., Ilyinsky V.V., Shuster A.M., Kudlay D.A. Experience of using Elizaria® in atypical hemolytic uremic syndrome. Pediatriya. Zhurnal im. G.N. Speranskogo = Pediatria. Journal named after G.N. Speransky 2019;98(5):225–9. (In Russ.).

28. Ptushkin V.V., Kulagin A.D., Lukina E.A., Davydkin I.L., Konstantinova T.S., Shamrai V.S., Minaeva N.V., Kudlay D.A., Gapchenko E.V., Markova O.A., Borozinets A.Yu. Results of phase Ib open multicenter clinical trial of the safety, pharmacokinetics and pharmacodynamics of first biosimilar of eculizumab in untreated patients with paroxysmal nocturnal hemoglobinuria during induction of therapy. Terapevticheskiy arkhiv = Therapeutic Archive 2020;92(7):77–84. (In Russ.). doi: 10.26442/00403660.2020.07.000818.

29. Kulagin A., Ptushkin V., Lukina E., Gapchenko E., Markova O., Zuev E., Kudlay D. Phase III clinical trial of Elizaria® and Soliris® in adult patients with paroxysmal nocturnal hemoglobinuria: results of comparative analysis of efficacy, safety, and pharmacological data. Blood 2019;134(Supp1):3748. doi: https://doi.org/10.1182/blood-2019-125693.